ORMP Archives - BioTuesdays

Developments

Oramed oral insulin flunks Phase 3 Type 2 diabetes trial

Oramed Pharmaceuticals’ (NASDAQ, TASE ORMP) oral insulin drug candidate, ORMD-0801, did not meet its primary endpoint in a Phase 3 clinical trial in patients with Type 2 diabetes (T2D) at 26 weeks. The multi-center ORA...

January 12, 2023

Developments

Oramed to commercialize oral insulin in Korea with Medicox

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) signed an exclusive commercial distribution agreement for the Republic of Korea with Medicox, an emerging biotech company with proven partnerships in the Korea. The agreement...

November 14, 2022

Developments

Oramed unit posts positive preliminary Phase 1 oral COVID-19 vaccine data

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) subsidiary, Oravax Medical, reported positive preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate. Oravax Medical is developing oral vaccines that...

October 7, 2022

Markets

Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...

February 18, 2022

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Developments

South Africa clears Phase 1 trial for Oramed oral COVID-19 vaccine

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) majority-owned subsidiary, Oravax Medical, received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in...

October 29, 2021

Developments

Oramed initiates Phase 3 oral insulin trials

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes. The trials will enroll a total of 1,125 Type 2 diabetes patients...

November 24, 2020

Developments

Oramed posts positive results in final cohort of Phase 2b oral insulin trial

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) reported positive topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, at lower...

February 26, 2020

Feature

Oramed hopes to start Phase 3 oral insulin trial next year

After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss proceeding...

August 23, 2016

Feature

Oramed sees value creating events through 2016

Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for oral insulin...

December 1, 2015

Tag - ORMP

Oramed oral insulin flunks Phase 3 Type 2 diabetes trial

Oramed to commercialize oral insulin in Korea with Medicox

Oramed unit posts positive preliminary Phase 1 oral COVID-19 vaccine data

Cantor starts Oramed at OW; PT $20

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

South Africa clears Phase 1 trial for Oramed oral COVID-19 vaccine

Oramed initiates Phase 3 oral insulin trials

Oramed posts positive results in final cohort of Phase 2b oral insulin trial

Oramed hopes to start Phase 3 oral insulin trial next year

Oramed sees value creating events through 2016

General

More